EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 26 / No 5 (Mai 2010) Med Sci (Paris), 26 5 (2010) 505-515 References
Free Access
Issue
Med Sci (Paris)
Volume 26, Number 5, Mai 2010
Page(s) 505 - 515
Section M/S revues
DOI https://doi.org/10.1051/medsci/2010265509
Published online 15 May 2010
  1. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol 1997; 123 : 199–206. [Google Scholar]
  2. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998; 116 : 1646–51. [Google Scholar]
  3. Klein BE, Klein R, Lee KE, et al. Risk of incident age-related eye diseases in people with an affected sibling: The Beaver Dam Eye study. Am J Epidemiol 2001; 154 : 207–11. [Google Scholar]
  4. Assink JJ, Klaver CC, Houwing-Duistermaat JJ, et al. Heterogeneity of the genetic risk in age-related macular disease: a population-based familial risk study. Ophthalmology 2005; 112 : 482–7. [Google Scholar]
  5. Luo L, Harmon J, Yang X, et al. Familial aggregation of age-related macular degeneration in the Utah population. Vision Res 2008; 48 : 494–500. [Google Scholar]
  6. Seddon JM, Cote J, Page WF, et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005; 123 : 321–7. [Google Scholar]
  7. Souied EH, Benlian P, Amouyel P, et al. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol 1998; 125 : 353–9. [Google Scholar]
  8. Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 1998; 63 : 200–6. [Google Scholar]
  9. Thakkinstian A, Bowe S, McEvoy M, et al. Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. Am J Epidemiol 2006; 164 : 813–22. [Google Scholar]
  10. Allikmets R, Shroyer NF, Singh N, et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 1997; 277 : 1805–7. [Google Scholar]
  11. Stone EM, Webster AR, Vandenburgh K, et al. Allelic variation in ABCR associated with Stargardt disease but not age-related macular degeneration. Nat Genet 1998; 20 : 328–9. [Google Scholar]
  12. Allikmets R. Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium. Am J Hum Genet 2000; 67 : 487–91. [Google Scholar]
  13. Baudouin C, Peyman GA, Fredj-Reygrobellet D, et al. Immunohistological study of subretinal membranes in age-related macular degeneration. Jpn J Ophthalmol 1992; 36 : 443–51. [Google Scholar]
  14. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20 : 705–32. [Google Scholar]
  15. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308 : 385–9. [Google Scholar]
  16. Souied EH, Leveziel N, Richard F, et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis 2005; 11 : 1135–40. [Google Scholar]
  17. Gotoh N, Yamada R, Hiratani H, et al. No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum Genet 2006; 120 : 139–43. [Google Scholar]
  18. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 2006; 15 : 2784–90. [Google Scholar]
  19. Seddon JM, Santangelo SL, Book K, et al. A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. Am J Hum Genet 2003; 73 : 780–90. [Google Scholar]
  20. Jakobsdottir J, Conley YP, Weeks DE, et al. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 2005; 77 : 389–407. [Google Scholar]
  21. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005; 14 : 3227–36. [Google Scholar]
  22. Chien J, Staub J, Hu SI, et al. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 2004; 23 : 1636–44. [Google Scholar]
  23. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314 : 989–92. [Google Scholar]
  24. Chen W, Xu W, Tao Q, et al. Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration. Exp Eye Res 2009; 89 : 292–300. [Google Scholar]
  25. Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 2007; 104 : 16227–32. [Google Scholar]
  26. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314 : 989–92. [Google Scholar]
  27. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006; 314 : 992–3. [Google Scholar]
  28. Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008; 40 : 892–6. [Google Scholar]
  29. Conley YP, Jakobsdottir J, Mah T, et al. CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. Hum Mol Genet 2006; 15 : 3206–18. [Google Scholar]
  30. Seddon JM, Francis PJ, George S, et al. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 2007; 297 : 1793–800. [Google Scholar]
  31. Seddon JM, Reynolds R, Maller J, et al. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci 2009; 50 : 2044–53. [Google Scholar]
  32. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol 2002; 86 : 663–9. [Google Scholar]
  33. Cohen SY, Creuzot-Garcher C, Darmon J, et al. Types of choroidal neovascularization (CNV) in newly diagnosed exudative age-related macular degeneration (AMD). Br J Ophthalmol 2007; 91 : 1173–6. [Google Scholar]
  34. Leveziel N, Zerbib J, Richard F, et al. Genotype-phenotype correlation for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes. Invest Ophthalmol Vis Sci 2008; 49 : 3090–4. [Google Scholar]
  35. Wegscheider BJ, Weger M, Renner W, et al. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. Ophthalmology 2007; 114 : 738–42. [Google Scholar]
  36. Droz I, Mantel I, Ambresin A, et al. Genotype-phenotype correlation of age-related macular degeneration: influence of complement factor H polymorphism. Br J Ophthalmol 2008; 92 : 513–7. [Google Scholar]
  37. Leveziel N, Puche N, Richard F, et al. Genotypic influences on severity of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2010 (sous presse). [Google Scholar]
  38. Sakurada Y, Kubota T, Imasawa M, et al. Angiographic lesion size associated with LOC387715 A69S genotype in subfoveal polypoidal choroidal vasculopathy. Retina 2009; 29 : 1522–6. [Google Scholar]
  39. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 Genotypes and Treatment with Antioxidants and Zinc for Age-Related Macular Degeneration. Ophthalmology 2008; 115 : 1019–25. [Google Scholar]
  40. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 : 1419–31. [Google Scholar]
  41. Brown DM, Kaiser PK, Michels M, et al. Comparison of ranibizumab and verteporfin photodynamic therapy for neovascular age-related macular degeneration. N Engl J Med 2006; 355 : 1432–14. [Google Scholar]
  42. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114 : 2168–73. [Google Scholar]
  43. Leveziel N, Soubrane G, H Souied E. Anti-VEGF : applications pratiques en ophtalmologie. Med Sci (Paris) 2009; 25 : 1105–7. [Google Scholar]
  44. Brantley MA Jr, Edelstein SL, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye (Londres) 2009; 23 : 626–31. [Google Scholar]
  45. Lin JM, Wan L, Tsai YY, et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol 2008; 145 : 1045–51. [Google Scholar]
  46. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 2006; 47 : 329–335. [Google Scholar]
  47. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006; 15 : 2955–61. [Google Scholar]
  48. Behar-Cohen F, Sennlaub F, Berdugo M. Espoirs thérapeutiques dans la DMLA. Med Sci (Paris) 2007; 23 : 127–9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.